UK's NICE backs Novo Nordisk's Victoza in revised preliminary recommendation; firm discontinues some products in UK

15 June 2010

The National Institute of Clinical Excellence (NICE), the rationing body for medical treatment under the UK's National Health Service in England and Wales, yesterday released a revised preliminary recommendation on the use of Danish insulin giant Novo Nordisk's Victoza (liraglutide) for patients with type 2 diabetes, following a second appraisal committee meeting held in April. Final guidance is expected as early as October this year.

Victoza is a once-daily injectable human GLP-1 analog licensed in Europe, the USA, Japan and India. It has been available in the UK since July 2009 for people with type 2 diabetes in combination with oral anti-diabetic tablets.

The newly revised preliminary recommendation maintains the positioning of liraglutide issued by the NICE in February this year. It also includes a recommendation that liraglutide 1.2mg daily is a clinically and cost-effective treatment option, for use in combination with one oral anti-diabetic tablet (metformin or a sulphonylurea) for treatment in people with type 2 diabetes if:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK